Amneal Biosciences unveils generic triamcinolone acetonide injectable suspension in the market
13 December 2017 -

Pharmaceuticals company Amneal Biosciences disclosed on Tuesday the approval and availability of its Triamcinolone Acetonide Injectable Suspension, USP in 40 mg/ml dosage strength directly and through wholesalers and distributors.

According to the company, its triamcinolone acetonide will be sold in 1 ml single-dose vials as well as in 5 ml and 10 ml multiple dose vials.

The company added the triamcinolone acetonide injectable suspension is the only AP-rated generic equivalent to KenalogR-40 injection available in the market.

Annually, the US sales of Kenalog-40 injection were USD146m, according to October 2017 IQVIA market data, concluded the company.